.png)
Health Law Alliance is pleased to announce that a “fraud” self-disclosure filed under Anthony Mahajan’s oversight was recently accepted into OIG’s self-disclosure program, effectively limiting the provider’s liability for alleged improper billing.
OIG’s Self-Disclosure Protocol
The U.S. Department of Health and Human Services, Office of the Inspector General (OIG), encourages providers to voluntarily report self-discovered evidence of potential fraud through the Health Care Fraud Self-Disclosure Protocol.
As we have written about in detail, a discrepant PBM audit may permit providers to learn about and resolve potential liabilities to government healthcare programs through the OIG self-disclosure process. Please read our article, “PBM Audit Strategy: Potential Windows of Opportunity,” available HERE, to learn more.
In short, self-disclosure often presents an excellent opportunity for providers to limit their exposure under administrative, civil, and maybe even criminal law, but the determination whether to make such a voluntary disclosure is extremely complex and must be carefully vetted by experienced healthcare defense attorneys.
The Provider’s OIG Disclosure
Per OIG’s announcement, following a self-disclosure submitted pursuant to the Self-Disclosure Protocol, Shore Orthopaedic University Associates, P.A., Charles N. Krome, D.O., and OrthoNJ, LLC, agreed to pay $333,645.83 for allegedly submitting claims to federal health care programs using code Q4206 for the use of Fluid Flow, an amniotic fluid growth factor injection product that treats orthopedic patients, to treat conditions which were not approved by Medicare.
In short, billing Medicare for products used to treat unapproved conditions exposes a provider to significant potential consequences. In this case, the decision was made to self-disclose after extensive consideration of many factors, including the calculation of damages, minimum settlement amounts, the conduct at issue, and the potential that the disclosure would not be accepted by OIG.
HLA Specializes in OIG Self-Disclosures
At Health Law Alliance, our experienced healthcare defense attorneys are specialists in all relevant self-disclosure protocols and procedures. Indeed, our attorneys possess the background and experience necessary to provide guidance and legal advice related to self-disclosures and assist with each step of the self-disclosure process. Contact us today for a free consultation.
Triumph Over Optum: HLA’s Tenacious Advocacy Reverses Optum’s Termination of a Texas Pharmacy
Health Law Alliance successfully reversed Optum’s termination of a Texas pharmacy from its network, protecting the pharmacy from severe financial and reputational damage. Our healthcare attorneys used strategic legal expertise and negotiations to overturn the decision, ensuring the pharmacy could continue serving patients. This victory highlights our dedication to strong advocacy and proven results.
Read More >>Enforcement of Arbitration Clauses in PBM Network Agreements: A Guide for Pharmacy Owners
This article explains arbitration clauses in Pharmacy Benefit Manager (PBM) network agreements, outlining when these clauses can be enforced and how they affect dispute resolution for pharmacies.
Read More >>U.S. Justice Department Investigates Alleged Medicare Fraud Involving COVID-19 Test Kits
The U.S. Justice Department is investigating allegations of Medicare fraud, where senior citizens' ID numbers were used to order unwanted COVID-19 test kits. Learn more about the ongoing investigation and its implications.
Read More >>HLA Convinces Optum to Reverse PBM Audit Termination
Health Law Alliance is pleased to announce that Optum recently agreed to reverse its network termination of a Texas pharmacy client despite significant claim discrepancies based on inventory shortages, patient denials, and other alleged violations of the terms and conditions of the Provider Manual and network enrollment agreements.
Read More >>.png)